Metacrine (NASDAQ:MTCR) Trading Down 1.6%

Metacrine, Inc. (NASDAQ:MTCR – Get Rating) fell 1.6% during trading on Thursday . The stock traded as low as $0.46 and last traded at $0.47. 568,816 shares were traded during mid-day trading, a decline of 63% from the average session volume of 1,537,161 shares. The stock had previously closed at $0.48.

The company has a current ratio of 12.19, a quick ratio of 12.19 and a debt-to-equity ratio of 0.29. The stock has a market cap of $19.96 million, a P/E ratio of -0.23 and a beta of -1.11. The firm’s 50-day simple moving average is $0.47 and its 200 day simple moving average is $0.58.

Metacrine (NASDAQ:MTCR – Get Rating) last posted its earnings results on Wednesday, March 30th. The company reported ($0.44) EPS for the quarter, topping the consensus estimate of ($0.68) by $0.24. On average, analysts anticipate that Metacrine, Inc. will post -1.15 EPS for the current year.

Institutional investors have recently bought and sold shares of the company. Bank of America Corp DE grew its position in Metacrine by 10.5% in the first quarter. Bank of America Corp DE now owns 263,340 shares of the company’s stock worth $161,000 after buying an additional 24,964 shares during the last quarter. ARCH Venture Management LLC acquired a new position in shares of Metacrine in the 1st quarter worth $1,793,000. Renaissance Technologies LLC grew its holdings in shares of Metacrine by 84.5% in the 1st quarter. Renaissance Technologies LLC now owns 423,100 shares of the company’s stock worth $258,000 after acquiring an additional 193,800 shares during the last quarter. Bank of New York Mellon Corp acquired a new stake in shares of Metacrine during the first quarter worth $126,000. Finally, Acadian Asset Management LLC acquired a new stake in shares of Metacrine during the fourth quarter worth $56,000. Institutional investors and hedge funds own 13.49% of the company’s stock.

About Metacrine (NASDAQ:MTCR)

Metacrine, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc was incorporated in 2014 and is headquartered in San Diego, California.

Featured Stories